Trial Profile
A Phase I, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of GW572016 in Combination With Docetaxel (Taxotere)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Docetaxel
- Indications Breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors GSK
- 08 Dec 2017 New trial record